Quarterly Activities Report
for the period ending 30 September 2025

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to present its activities report for the quarter ended 30 September 2025 (Q1 FY2026), together with its Appendix 4C Quarterly Cash Flow Report.

R&D UPDATES

NTI164

Initiation of NTI164 Authorised Prescriber Program

In September, Neurotech initiated an Authorised Prescriber (AP) program for its lead investigational therapy, NTI164 (ASX announcement: 23 September 2025). A significant milestone in the Company's strategy to expand access and advance the commercialisation of treatments for paediatric neurological disorders in Australia.

The program will be overseen by Professor Michael Fahey, Head of Paediatric Neurology at Monash Medical Centre, enables controlled and specialist-led access to NTI164 for eligible children with a range of neurodevelopmental conditions. It has been established in response to growing demand from families seeking access to the therapy, which has shown clinically meaningful results in clinical trials but remains limited in availability under those trial settings.

Through the AP framework, patients outside of formal studies will be able to access NTI164 under strict clinical supervision, ensuring safety and consistency in care. The program also serves a critical data-gathering function, with real-world clinical outcomes expected to complement Neurotech's ongoing and planned clinical trials. These real-world insights will strengthen the Company's regulatory submissions, advocacy efforts, and future discussions with potential partners as NTI164 progresses toward pivotal trials and registration.

Importantly, the program is structured to be self-sustaining rather than profit-driven, with pricing set to cover the cost of supply plus a modest margin. This ensures that Neurotech can provide broader access while maintaining financial neutrality, using the initiative primarily as a mechanism for data generation and early market establishment.

The timing of the program also aligns with the evolving NDIS policy landscape, particularly the forthcoming reforms that will see children with mild to moderate autism spectrum disorder moved off the NDIS and into new support pathways by 2027. By generating real-world data through the AP program, Neurotech aims to ensure that NTI164 is well positioned within this new framework, demonstrating its clinical and social value to healthcare decision-makers and policymakers.

Rett Syndrome

US FDA Rare Pediatric Disease Designation for NTI164

Following the end of the quarter, Neurotech received Rare Paediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) for its lead candidate, NTI164, in the treatment of Rett Syndrome, marking another significant regulatory milestone for the Company (ASX

announcement: 8 October 2025). This designation complements the previously granted Orphan Drug Designations, reinforcing Neurotech's strategic position in developing NTI164 for rare and severe paediatric neurological conditions, targeting diseases affecting fewer than 200,000 people in the United States and offers several advantages, including enhanced FDA guidance, eligibility for priority review, tax credits for clinical testing, exemption from certain FDA fees, and seven years of market exclusivity in the US subject to approval.

The FDA's decision was based on its determination that Rett Syndrome is a serious, life-threatening, and rare disease under section 526 of the Federal Food, Drug, and Cosmetic Act. The designation provides valuable regulatory support and further validates the therapeutic potential of NTI164, a unique anti-inflammatory and neuroprotective compound derived from a proprietary Cannabis sativa strain.

Clinical Trial Results Published in Renowned Scientific Journal

In July, the Company announced the publication of Phase I/II clinical trial results for NTI164 in Rett syndrome in the Journal of Paediatrics and Child Health (ASX announcement: 7 July 2025).

The peer-reviewed paper, titled "Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) Improves Symptoms of Rett Syndrome: An Open-Label Study", presents detailed findings from Neurotech's open-label clinical trial evaluating NTI164, a novel full-spectrum medicinal cannabis extract containing 0.08% THC.

The study demonstrated that NTI164 was well tolerated and showed clinical improvements across multiple domains relevant to Rett syndrome, including neurological, behavioural, and functional outcomes. These findings suggest NTI164 may provide broader therapeutic benefits for patients beyond symptom management.

The authors concluded that the data provide compelling evidence supporting NTI164 as a potential therapy for Rett syndrome, with the findings reinforcing its proposed mechanism of action in modulating neuroinflammation, glial dysregulation, and synaptic function.

A copy of the publication is available at: https://pubmed.ncbi.nlm.nih.gov/40568811/

Advancing Long-Term Safety and Regulatory Progress

Chronic Toxicology Program

Neurotech is diligently progressing its chronic toxicology study for NTI164, designed to demonstrate the long-term safety profile of the compound in alignment with U.S. Food and Drug Administration (FDA) requirements. This important program represents a key component of the Company's broader regulatory and registration strategy, supporting future clinical and commercial pathways in both the United States and other global markets.

Regulatory Strategy

The Company continues to make strong progress toward the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NTI164. This program represents a pivotal step in the Company's global regulatory strategy, aimed at expanding clinical development into the United States and Australia. The Company is in the process of planning further clinical studies, including a Phase III registration study in autism spectrum disorder.

CORPORATE ACTIVITIES

Progressing Partnering

Neurotech remains highly active in engaging with key industry and investment stakeholders, participating in major events such as the BIO International Convention in the United States in June and the Bioshares Biotech Summit in Australia in August. These engagements have provided excellent opportunities to showcase Neurotech's strong clinical progress, strengthen relationships, and further elevate the Company's profile among potential partners and investors.

The Company has engaged in numerous preliminary discussions with parties expressing interest. Encouragingly, several of these interactions, although incomplete, have progressed to more advanced confidential stages.

Appendix 4C Commentary

During the quarter, the Company recorded total cash operating expenses (excluding revenue sources) of ~$1.2 million (Q4 FY2025: $2.6 million), consisting of research and development costs of ~$0.8 million (Q4 FY2025: $2.2 million), along with advertising, marketing, staff, administrative, and corporate costs of ~$0.4 million (Q4 FY2025: $0.4 million).

Total operating cash outflows for the quarter were ~$1.2 million (Q4 FY2025: $2.6 million). R&D expenditure during the quarter reflected investment into the IND enabling pre-clinical toxicology work required to support an FDA IND and TGA applications, along with extension phase costs of the Phase II/III ASD clinical trial, Phase I/II clinical trials in Rett Syndrome, maintenance costs associated with children migrating to extension phases of previous clinical trials, along with drug product manufacturing costs and regulatory development.

The Company closed the quarter with cash and cash equivalents of ~$1.7 million (Q4 FY25: $3 million). NTI expects to receive cash inflows from the R&D Tax Incentive of approximately $4.7m in the current quarter (Q2 FY2026). The Company has received a positive Advanced Overseas Finding (AOF) outcome for some of its overseas activities, resulting in a revised refundable tax offset of ~$4.7 million (previously estimated to be $3.2 million).

Further, payments to related parties and their associates as detailed in Section 6 of the Appendix 4C totalled $127,000.

This announcement has been authorised for release by the Board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About Neurotech

Neurotech International Limited (ASX:NTI)) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit http://www.neurotechinternational.com.

Neurotech International Ltd
Suite 5 CPC, 145 Stirling Highway
Nedlands, Western Australia 6009

T: +61 (8) 9389 3130
E: info@neurotechinternational.com
W: neurotechinternational.com

ABN: 73 610 205 402
ASX: NTI

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Neurotech International Limited	
ABN	**Quarter ended ("current quarter")**
73 610 205 402	30 September 2025

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	0	0
1.2	Payments for		
	(a) research and development	(819)	(819)
	(b) product manufacturing and operating costs	0	0
	(c) advertising and marketing	(76)	(76)
	(d) leased assets	0	0
	(e) staff costs	(78)	(78)
	(f) administration and corporate costs	(287)	(287)
1.3	Dividends received (see note 3)	0	0
1.4	Interest received	4	4
1.5	Interest and other costs of finance paid	(1)	(1)
1.6	Income taxes paid	0	0
1.7	Government grants and tax incentives (R&D Rebate)	0	
1.8	Other (GST refunds)	0	0
1.9	**Net cash from / (used in) operating activities**	**(1,257)**	**(1,257)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	0	0
	(b) businesses	0	0
	(c) property, plant and equipment	0	0
	(d) investments	0	0
	(e) intellectual property	0	0

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
	(f) other non-current assets	0	0
2.2	Proceeds from disposal of:		
	(a) entities	0	0
	(b) businesses	0	0
	(c) property, plant and equipment	0	0
	(d) investments	0	0
	(e) intellectual property	0	0
	(f) other non-current assets	0	0
2.3	Cash flows from loans to other entities	0	0
2.4	Dividends received (see note 3)	0	0
2.5	Other (provide details if material)	0	0
2.6	**Net cash from / (used in) investing activities**	**0**	**0**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	0	0
3.2	Proceeds from issue of convertible debt securities	0	0
3.3	Proceeds from exercise of options	0	0
3.4	Transaction costs related to issues of equity securities or convertible debt securities	0	0
3.5	Proceeds from borrowings	0	0
3.6	Repayment of borrowings	0	0
3.7	Transaction costs related to loans and borrowings	0	0
3.8	Dividends paid	0	0
3.9	Other (provide details if material)	0	0
3.10	**Net cash from / (used in) financing activities**	**0**	**0**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	3,032	3,032
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,257)	(1,257)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	0	0

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	0	0
4.5	Effect of movement in exchange rates on cash held	0	0
4.6	**Cash and cash equivalents at end of period**	**1,775**	**1,775**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	1,760	3,017
5.2	Call deposits	15	15
5.3	Bank overdrafts	0	0
5.4	Other (provide details)	0	0
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,775**	**3,032**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	127
6.2	Aggregate amount of payments to related parties and their associates included in item 2	0

Payments at section 6. relate to director fees ($50,000), executive salaries and reimbursement ($77,000).

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	71	0
7.2	Credit standby arrangements	0	0
7.3	Other (please specify)	0	0
7.4	**Total financing facilities**	71	0

7.5	**Unused financing facilities available at quarter end**	71

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Overdraft facility with a limit of EUR 40,000. The lender is Bank of Valetta. The facility is unsecured. The interest rate is 5.65%.

The above values are stated in AUD, converted from EUR at an exchange rate of 0.559.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,257)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,775
8.3	Unused finance facilities available at quarter end (item 7.5)	71
8.4	Total available funding (item 8.2 + item 8.3)	1,846
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	1.47

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

The company expects that net operating cash flows will remain broadly consistent in the near term, reflecting ongoing expenditure associated with continued R&D activities, and normal operating costs. The level of expenditure may fluctuate between quarters depending on the timing of activities.

8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?
	The company continues to monitor its funding position and expenditure requirements closely. NTI expects to receive cash inflows from the R&D Tax Incentive of approximately $4.7m in the current quarter (Q2 FY2026). The Company has received a positive Advanced Overseas Finding (AOF) outcome for some of its overseas activities, resulting in a revised refundable tax offset of $4.7 million (previously estimated to be $3.2 million).
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
	Yes. Refer to 8.6.2.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 28 October 2025
.....

Authorised by: The Board of Directors
.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.